用奥曲肽成功治疗严重难治性磺脲类药物所致低血糖症。
Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide.
作者信息
Krentz A J, Boyle P J, Justice K M, Wright A D, Schade D S
机构信息
Diabetic Clinic, General Hospital, Birmingham, United Kingdom.
出版信息
Diabetes Care. 1993 Jan;16(1):184-6. doi: 10.2337/diacare.16.1.184.
OBJECTIVE
To test the clinical use of octreotide in the treatment of sulfonylurea-induced hypoglycemia.
RESEARCH DESIGN AND METHODS
A case is reported of sulfonylurea-induced hypoglycemic coma in a nondiabetic subject, which was complicated by relapse of hypoglycemia after resuscitation with intravenous dextrose. Subcutaneous octreotide, 50 micrograms 12 hourly, suppressed stimulated endogenous insulin secretion, thereby preventing a further recurrence of hypoglycemia.
RESULTS
No adverse effects of treatment were observed.
CONCLUSIONS
These results suggest a significant role for octreotide as an adjunct to intravenous dextrose in the management of severe and refractory cases of sulfonylurea-induced hypoglycemia.
目的
测试奥曲肽在治疗磺脲类药物所致低血糖症中的临床应用。
研究设计与方法
报告一例非糖尿病患者发生磺脲类药物所致低血糖昏迷的病例，该患者在静脉输注葡萄糖复苏后出现低血糖复发。每12小时皮下注射50微克奥曲肽可抑制内源性胰岛素分泌，从而防止低血糖再次发生。
结果
未观察到治疗的不良反应。
结论
这些结果表明，在磺脲类药物所致严重和难治性低血糖症的管理中，奥曲肽作为静脉输注葡萄糖的辅助药物具有重要作用。
Zotero 插件